File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A synopsis of current haemophilia care in Hong Kong

TitleA synopsis of current haemophilia care in Hong Kong
Authors
KeywordsFactor VIII
Hemophilia A
HIV infections
Mutation
Survival rate
Issue Date2011
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal, 2011, v. 17 n. 3, p. 189-194 How to Cite?
AbstractObjective To provide a synopsis of current haemophilia care in Hong Kong. Design Retrospective survey. Setting All haematology units of the Hospital Authority in Hong Kong. Patients All patients with haemophilia A and haemophilia B. Results To date, there were 222 mild-to-severe haemophilia patients (192 type A, 30 type B) under regular public care in Hong Kong (43% were considered severe, 33% moderate, and 24% mild), which gave a crude prevalence of 6.8/100 000 male inhabitants. A total of 12.8 million units of Factor VIII and 3 million units of Factor IX were prescribed annually. This amounts to 1.83 units of FVIII per capita of the population, which is comparable to that of other developed countries. Leading causes of mortality were human immunodefciency virus-related complications (10 cases) and cerebral bleeding (2 cases). The life expectancy of patients with severe haemophilia in Hong Kong is improving; currently the oldest patient is 60 years old. Such improved survival may be due to enhanced factor availability, prompt treatment of bleeding episodes at home, safer factor products, and better antiviral treatment. Primary prophylaxis is the accepted standard of care for severe and moderate cases, and "Factor First" has become hospital policy. However, 12 patients continue to present treatment challenges, due to the documented presence of factor inhibitors. In all, 28,100, and 14 cases respectively were positive for human immunodefciency virus, hepatitis C virus, and hepatitis B virus; the youngest patients with the corresponding infections being 28,13, and 22 years old. Comprehensive care with dedicated physiotherapy, surgical support, and radionucleotide synovectomy may reduce morbidity further. Conclusion A multidisciplinary approach can further improve the future care for haemophilia patients in Hong Kong.
Persistent Identifierhttp://hdl.handle.net/10722/135337
ISSN
2014 Impact Factor: 0.872
2014 SCImago Journal Rankings: 0.237
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorLee, Ven_HK
dc.contributor.authorKho, Ben_HK
dc.contributor.authorLing, ASCen_HK
dc.contributor.authorChan, Den_HK
dc.contributor.authorChan, EYTen_HK
dc.contributor.authorChan, GCFen_HK
dc.contributor.authorCheung, WWWen_HK
dc.contributor.authorLau, CWen_HK
dc.contributor.authorLee, CYen_HK
dc.contributor.authorLi, RCHen_HK
dc.contributor.authorLi, CKen_HK
dc.contributor.authorLin, SYen_HK
dc.contributor.authorMak, Ven_HK
dc.contributor.authorSun, Len_HK
dc.contributor.authorWong, KHFen_HK
dc.contributor.authorWong, Ren_HK
dc.contributor.authorYau, Jen_HK
dc.contributor.authorYuen, HLen_HK
dc.date.accessioned2011-07-27T01:33:44Z-
dc.date.available2011-07-27T01:33:44Z-
dc.date.issued2011en_HK
dc.identifier.citationHong Kong Medical Journal, 2011, v. 17 n. 3, p. 189-194en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/135337-
dc.description.abstractObjective To provide a synopsis of current haemophilia care in Hong Kong. Design Retrospective survey. Setting All haematology units of the Hospital Authority in Hong Kong. Patients All patients with haemophilia A and haemophilia B. Results To date, there were 222 mild-to-severe haemophilia patients (192 type A, 30 type B) under regular public care in Hong Kong (43% were considered severe, 33% moderate, and 24% mild), which gave a crude prevalence of 6.8/100 000 male inhabitants. A total of 12.8 million units of Factor VIII and 3 million units of Factor IX were prescribed annually. This amounts to 1.83 units of FVIII per capita of the population, which is comparable to that of other developed countries. Leading causes of mortality were human immunodefciency virus-related complications (10 cases) and cerebral bleeding (2 cases). The life expectancy of patients with severe haemophilia in Hong Kong is improving; currently the oldest patient is 60 years old. Such improved survival may be due to enhanced factor availability, prompt treatment of bleeding episodes at home, safer factor products, and better antiviral treatment. Primary prophylaxis is the accepted standard of care for severe and moderate cases, and "Factor First" has become hospital policy. However, 12 patients continue to present treatment challenges, due to the documented presence of factor inhibitors. In all, 28,100, and 14 cases respectively were positive for human immunodefciency virus, hepatitis C virus, and hepatitis B virus; the youngest patients with the corresponding infections being 28,13, and 22 years old. Comprehensive care with dedicated physiotherapy, surgical support, and radionucleotide synovectomy may reduce morbidity further. Conclusion A multidisciplinary approach can further improve the future care for haemophilia patients in Hong Kong.en_HK
dc.languageengen_US
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_HK
dc.relation.ispartofHong Kong Medical Journalen_HK
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectFactor VIIIen_HK
dc.subjectHemophilia Aen_HK
dc.subjectHIV infectionsen_HK
dc.subjectMutationen_HK
dc.subjectSurvival rateen_HK
dc.subject.meshCoagulants - therapeutic use-
dc.subject.meshFactor IX - therapeutic use-
dc.subject.meshFactor VIII - therapeutic use-
dc.subject.meshHemophilia A - epidemiology - physiopathology - therapy-
dc.subject.meshHemophilia B - epidemiology - physiopathology - therapy-
dc.titleA synopsis of current haemophilia care in Hong Kongen_HK
dc.typeArticleen_HK
dc.identifier.emailChan, GCF:gcfchan@hkucc.hku.hken_HK
dc.identifier.authorityChan, GCF=rp00431en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.pmid21636866-
dc.identifier.scopuseid_2-s2.0-79958745818en_HK
dc.identifier.hkuros187929en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79958745818&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume17en_HK
dc.identifier.issue3en_HK
dc.identifier.spage189en_HK
dc.identifier.epage194en_HK
dc.publisher.placeHong Kongen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridLee, V=35113525600en_HK
dc.identifier.scopusauthoridKho, B=8501559600en_HK
dc.identifier.scopusauthoridLing, ASC=36515085000en_HK
dc.identifier.scopusauthoridChan, D=8397272800en_HK
dc.identifier.scopusauthoridChan, EYT=34967865700en_HK
dc.identifier.scopusauthoridChan, GCF=16160154400en_HK
dc.identifier.scopusauthoridCheung, WWW=8615134400en_HK
dc.identifier.scopusauthoridLau, CW=7401968318en_HK
dc.identifier.scopusauthoridLee, CY=38162990200en_HK
dc.identifier.scopusauthoridLi, RCH=24177143900en_HK
dc.identifier.scopusauthoridLi, CK=24554113600en_HK
dc.identifier.scopusauthoridLin, SY=34979792200en_HK
dc.identifier.scopusauthoridMak, V=43561528900en_HK
dc.identifier.scopusauthoridSun, L=35270743300en_HK
dc.identifier.scopusauthoridWong, KHF=35097874900en_HK
dc.identifier.scopusauthoridWong, R=12344554600en_HK
dc.identifier.scopusauthoridYau, J=36515869900en_HK
dc.identifier.scopusauthoridYuen, HL=7103253677en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats